News und Analysen
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Novocure to Report Second Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management
DGAP-News: MicroVision's Germany Test Vehicle to Showcase Product to OEMs; Second Highway-Speed Track Testing Completed
Dexcom Schedules Second Quarter 2022 Earnings Release and Conference Call for July 28, 2022 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022. Management will hold a conference call
Acadia Healthcare Forms Joint Venture With Tufts Medicine to Build a Behavioral Health Hospital to Serve the Boston Regional Area
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Tufts Medicine, one of Massachusetts’ elite health systems. The partnership anticipates
Tufts Medicine and Melrose Wakefield Hospital Partner With Acadia Healthcare to Build Inpatient Behavioral Health Hospital to Serve Regional Boston Area
Tufts Medicine, a leading Massachusetts consumer oriented health system, and Acadia Healthcare Company, the largest standalone provider of behavioral health services in the U.S., announced today
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record-setting attendance and
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement
Chemed Corporation Announces a Five-Year $550 Million Amended and Restated Senior Secured Credit Facility
Chemed Corporation ("Chemed") (NYSE:CHE) announced that it has entered into $550 million of amended and restated senior secured credit facilities (“Credit Facilities”). JPMorgan Chase Bank, N.A
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose
Pfizer Declares Third-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 third-quarter 2022 dividend on the company’s common stock, payable September 6, 2022, to holders of the Common
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
Charles River Laboratories International, Inc. (NYSE: CRL) and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products for vaccine and
Premier Inc. Honors Indiana Recovery Home for Women with National Award and $100,000 Prize
The BreakAway, a nonprofit dedicated to helping women recover from the disease of addiction in New Albany, IN, has received the 2022 Monroe E. Trout Premier Cares Award and a $100,000 cash prize
Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County
QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) — QuidelOrtho announces that its subsidiary, Quidel Corporation, is collaborating with the American Heart Association, the leading voluntary
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the third quarter of fiscal year 2022, the period ended May 31, 2022, after the close of the
Henry Ford Health Wins 2022 Premier Alliance Excellence Award
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has named Henry Ford Health, an integrated nonprofit health system providing a full continuum of services
Agilent Laboratory Achieves Green Lab Certification
Agilent Technologies Inc. (NYSE: A) today announced that the company’s customer demonstration laboratory in Waldbronn, Germany has received the highest level of Green Lab Certification, the gold
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway
Waters and BioInfra Establish the ASEAN Academy for Bioanalysis to Promote Analytical Skills Development
Waters Corporation (NYSE:WAT) announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine